The NEST-1 study, which is evaluating botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colorectal cancer, both those with Microsatellite Stable (MSS) CRC and Microsatellite Instability High CRC (MSI-High), has demonstrated positive results.
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
